Researchers have proposed a new way to label obesity that goes beyond BMI, adding waist measurements and body fat distribution into the mix, and that shift would push the U.S. adult obesity estimate from about 43% to roughly 70%. The change comes from an analysis of roughly 300,000 people and highlights how where fat sits on the body can matter far more for health than weight alone. Clinicians warn this will reshape who gets clinical attention, who becomes eligible for medications, and how we talk about risk. The debate now centers on targeting visceral fat and metabolic danger instead of obsessing over the scale.
The team behind the work used measures that identify fat patterns rather than only total mass, and those patterns revealed a much wider group at elevated risk. Adding waist circumference and body fat location showed many people who seemed healthy by BMI actually carry metabolically risky fat. Older adults were the most affected, with nearly eight in ten over 70 falling into the new obesity category. That demographic detail matters because risk and treatment priorities differ with age.
The limits of BMI have been obvious to clinicians for years: it tallies mass without distinguishing muscle from fat or where fat collects. Visceral fat, the deep abdominal fat that surrounds organs, behaves like an active organ itself and drives inflammation and insulin problems. That link helps explain why two people with identical BMIs can have very different cardiovascular and metabolic profiles. Shifting the definition to include distribution makes the risk picture sharper and more actionable.
WHAT YOUR BUTT SHAPE COULD REVEAL ABOUT YOUR HEALTH, ACCORDING TO SCIENTISTS
Experts say the reclassification could alter clinical triage and who gets prioritized for preventive care. “We already thought we had an obesity epidemic, but this is astounding,” she said. “With potentially 70% of the adult population now considered to have excess fat, we need to better understand what treatment approaches to prioritize.” That quote captures both surprise and the practical question clinics now face about resource allocation.
Endocrinologists note visceral fat is especially pernicious because of its ties to diabetes, high blood pressure, lipid problems and heart disease. “In addition, more of these patients may become eligible for GLP‑1–based therapies than under prior definitions, with the potential to meaningfully reduce their future cardiovascular risk,” he added. That opens a policy conversation about expanding access to medications that change weight and metabolic trajectories, and whether expanded eligibility should be the main focus.
GLP-1 WEIGHT-LOSS MEDICATIONS LINKED TO IMPROVED CANCER SURVIVAL IN CERTAIN PATIENTS
Some clinicians welcome the new criteria as a chance to catch high-risk patients earlier, while others worry about mislabeling and stigma. “I have been watching this trend unfold in my clinic for years,” the Texas-based doctor told Fox News Digital. “What concerns me most is that headlines like this often rely almost exclusively on weight-based measures such as BMI, which are blunt tools and miss what actually drives long-term health risk.”
“From a physiologic and metabolic standpoint, fat distribution matters far more than body weight alone,” she added, emphasizing that where fat lives is key to understanding true danger. In her practice she sees patients who technically meet obesity thresholds by BMI but have robust muscle and low visceral fat, with healthy labs and low cardiovascular risk. “In my patient population, I routinely see individuals who technically meet criteria for obesity based on BMI, but have high lean muscle mass, relatively low visceral fat and excellent metabolic health,” she said.
Those clinically fit but BMI-labeled individuals account for a sizable minority, according to her experience. “This group represents roughly 20% of patients labeled as obese in my practice, and they require very different counseling and nutrition recommendations than patients with significant visceral adiposity.” That distinction matters because counseling, exercise plans and medication choices should reflect composition and metabolic markers, not just a number on the scale.
“Tools that assess body composition, waist circumference and markers of insulin resistance give us a far more accurate picture than the scale ever could,” she said, urging wider adoption of targeted assessments. If clinicians and health systems pivot to these measures, screening could better identify who needs intensive interventions and who benefits from different strategies. “But if we do not shift the conversation away from weight alone and toward body composition and fat distribution, we will continue to misclassify risk and miss opportunities for more personalized, effective care,” she added.
OPRAH JOINS WAVE OF CELEBRITIES WHO REVEALED DRAMATIC WEIGHT LOSS IN 2025
